全部文献期刊学位论文会议报纸专利标准年鉴图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Alecu I , Milenkova T , Turner SR
来源:[J].Drug Design, Development and Therapy(IF 3.486), 2018, Vol.Volume 12, pp.347-348DOAJ
摘要:Iulian Alecu, Tsveta Milenkova, Simon R Turner Research and Development, AstraZeneca UK Limited, Cambridge, UKThe tolerability profile of PARP inhibitors often includes hematologic toxicities, and the characterization of these adverse events is important to allow effective manage...
作者:Charles-André Philip , Ido Laskov , Marie-Claude Beauchamp ...
来源:[J].BMC Cancer(IF 3.333), 2017, Vol.17 (1)Springer
摘要:... We assessed the sensitivity of endometrial cancer cell lines to PARP inhibitors (olaparib and BMN-673) and a PI3K inhibitor (BKM-120), alone or in combination, in the context of their PTEN mutation status. We also highlighted a direct pathway linking PTEN to DNA repair.
作者:Zhou JX , Feng LJ , Zhang X
来源:[J].Drug Design, Development and Therapy(IF 3.486), 2017, Vol.Volume 11, pp.3009-3017DOAJ
摘要:Jian xin Zhou,1,* Li jin Feng,2,* Xi Zhang3 1Department of Gynecology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, 2Department of Pathology, Shanghai Tenth People’s Hospital, Tongji University, School of Medicine, Shanghai, 3Department of Radiation Oncology, Affiliated Hospital of Hebei University, Baoding, China *These authors contributed equally to this work Purpose: Hematologic toxicities, including neutropenia, thrombocytopenia, and anemia, are major adverse effects of PARP inhibitors...
作者:Maud Marques , Marie-Claude Beauchamp , Hubert Fleury ...
来源:[J].BMC Medicine(IF 6.679), 2015, Vol.13 (1)Springer
摘要:Abstract(#br) Background(#br)PARP inhibitors have shown promising clinical results in cancer patients carrying BRCA1/2 mutations. Their clinical efficacy could logically be influenced by PARP1 protein levels in patient tumors.(#br) Methods(#br)We screened three cohorts of pat...
作者:Luca Livraghi , Judy E. Garber
来源:[J].BMC Medicine(IF 6.679), 2015, Vol.13 (1)Springer
摘要:Abstract(#br)Poly(ADP-ribose) polymerases (PARP) are enzymes involved in DNA-damage repair. Inhibition of PARPs is a promising strategy for targeting cancers with defective DNA-damage repair, including BRCA1 and BRCA2 mutation-associated breast and ovarian cancers. Several PARP inhibitors...
作者:Xichun Hu , Wei Huang , Minhao Fan
来源:[J].Journal of Hematology & Oncology(IF 4.458), 2017, Vol.10 (1)Springer
摘要:... Three CDK4/6 inhibitors consistently improve objective response and progression-free survival; however, overall survival data are waited. Optimization of chemotherapy and endocrine strategies remains an unmet need. Check point inhibitor-based immunotherapy combined with chemo...
作者:Katarzyna Kluzek , Aneta Białkowska , Aleksandra Koczorowska ...
来源:[J].Postępy Higieny i Medycyny Doświadczalnej(IF 0.552), 2012, Vol.66 (855199), pp.372-384DOAJ
摘要:... One of the most promising molecular targets in cancer therapy is poly(ADP-ribose) polymerases (PARP). PARP play an essential role in repairing DNA strand breaks. Small molecule inhibitors of these enzymes have been developed and have proved to be extremely toxic for cancer ce...
作者:Hsiao-Ching Chuang , Naval Kapuriya , Samuel K. Kulp ...
来源:[J].Breast Cancer Research and Treatment(IF 4.469), 2012, Vol.134 (2), pp.649-659Springer
摘要:Abstract(#br)Despite recent advances in the clinical evaluation of various poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer (TNBC) patients, data defining potential anti-tumor mechanisms beyond PARP inhibition for these agents are lacking. To addre...
作者:Oreekha Amin , Marie-Claude Beauchamp , Paul Abou Nader ...
来源:[J].BMC Cancer(IF 3.333), 2015, Vol.15 (1)Springer
摘要:... Further, we hypothesized that IGF-1R inhibition might sensitize HR proficient cancers to Poly ADP ribose polymerase (PARP) inhibitors.(#br) Methods(#br)Using ovarian and breast cancer cellular models with known BRCA1 status, we evaluated their HR functionality by RAD51 foci f...
作者:Joyce F. Liu , Panagiotis A. Konstantinopoulos , Ursula A. Matulonis
来源:[J].Gynecologic Oncology(IF 3.929), 2014, Vol.133 (2), pp.362-369Elsevier
摘要:Abstract(#br)Clinical investigation of poly(ADP-ribose) polymerase (PARP) inhibitors for ovarian cancer treatment has rapidly evolved from observations of single-agent in vitro activity of these agents in BRCA -deficient cancer cells in 2005 to the initiation of multiple phase II...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×